For its first fiscal quarter (ending March 31), EOG Resources Inc. (NYSE: EOG) has reported a -10% decline in E.P.S. from $3.46 a year ago to $3.11 in the current quarter. However, this result exceeded […]
For its first fiscal quarter (ending March 31), Cinemark Holdings Inc (NYSE: CNK) has reported E.P.S. of $0.20 compared to $-0.03 a year ago. This result exceeded the consensus estimate of $-0.02 by $0.22. For […]
Bruker Corporation (NASDAQ: BRKR) has reported E.P.S. of $0.35 for its first fiscal quarter (ending March 31) versus $0.52 for the same period a year ago — a decline of -33%. This result fell short […]
Blueprint Medicines Corp (NASDAQ: BPMC) has reported earnings for its first fiscal quarter (ending March 31) of $1.45 versus a loss $-2.15 for the same period a year ago. This performance was $2.66 better than […]
Baxter International Inc (NYSE: BAX) has reported earnings for its first fiscal quarter (ending March 31) of $0.07 versus $0.00 for the same period a year ago. This result fell short of the consensus estimate […]
For its first fiscal quarter (ending March 31), Bausch Health Cos Inc (NYSE: BHC) has reported E.P.S. of $-0.17 compared to $-0.55 a year ago. This performance was $-1.00 short of the consensus estimate of […]
Ares Management Corp (NYSE: ARES) has reported E.P.S. of $0.33 for its first fiscal quarter (ending March 31) versus $0.49 for the same period a year ago — a decline of -33%. Relative to the […]
For its second fiscal quarter (ending March 31), Apple Inc (NASDAQ: AAPL) has reported a 0% change in E.P.S. from $1.53 a year ago to $1.53 in the current quarter. This result fell short of […]
Apollo Global Management Inc (NYSE: APO) has reported E.P.S. of $2.31 for its first fiscal quarter (ending March 31) versus $1.67 for the same period a year ago — an increase of 38%. This performance […]
Amgen Inc (NASDAQ: AMGN) has reported E.P.S. of $-0.21 for its first fiscal quarter (ending March 31) versus $5.32 for the same period a year ago — a decline of -104%. Relative to the consensus […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research